Kadoaki Oohashi

Medicine & Life Sciences

1. Adenocarcinoma of Lung 29%
2. Ado-Trastuzumab Emtansine 13%
3. Afatinib 14%
4. Anaplastic Lymphoma Kinase 22%
5. Bevacizumab 13%
6. Biopsy 6%
7. Bronchoscopy 9%
8. capmatinib 11%
9. Carboplatin 7%
10. Carcinogenesis 6%
11. Cell Line 10%
12. Cetuximab 7%
13. CH5424802 19%
14. Chemoradiotherapy 8%
15. Cisplatin 7%
16. Confidence Intervals 6%
17. Crizotinib 15%
18. Drug Therapy 9%
19. ErbB Receptors 87%
20. Erlotinib Hydrochloride 10%
21. Exons 15%
22. Fentanyl 6%
23. Furosemide 6%
24. Gefitinib 36%
25. Gene Dosage 6%
26. Gene Fusion 8%
27. Immunoglobulin G4-Related Disease 6%
28. Immunohistochemistry 6%
29. Japan 7%
30. Lung 23%
31. Lung Neoplasms 65%
32. Lymph Nodes 6%
33. Mannitol 6%
34. Midazolam 6%
35. mouse EGFR protein 7%
36. Mutation 54%
37. N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine 13%
38. naquotinib 6%
39. Neoplasms 26%
40. Non-Small Cell Lung Carcinoma 100%
41. Oncogenes 6%
42. osimertinib 27%
43. Progression-Free Survival 10%
44. Prospective Studies 8%
45. Protein-Tyrosine Kinases 41%
46. Safety 11%
47. Survival 9%
48. Therapeutics 12%
49. Transgenic Mice 10%
50. Vascular Endothelial Growth Factor Receptor-2 6%